Ryan Livingston

The updated recommendations encourage both patients and clinicians to take a more proactive approach to preventing or managing hypertension.

Recent research has shown long-lasting freedom of documented AF and atrial tachycardia.

Recent interview- and survey-based research has quantified the extent to which GPP impacts patients, examining both symptoms and mental health outcomes.

Parent company Response Pharmaceuticals has announced RDX-002’s achievement of its primary endpoint, with more data to come from an ongoing extension.

The 2 organizations released a joint statement on challenging the common view of HF as an inevitability and prioritizing preventive measures.

Over 11,000 bottles have been voluntarily recalled in response to a consumer complaint of a foreign substance inside a tablet, later identified as aluminum.

This new monoclonal antibody has achieved a statistically significant improvement in time to treatment failure, indicating a potential to revolutionize ITP.

Despite obesity’s well-known influence on AF recurrence, neither comorbidity has a significant influence on outcomes from early rhythm control therapy.

A month with few regulations instead saw significant research advancements presented at the American Society of Retina Specialists’ 2025 meeting.

The larger dose exhibited better gains in best-corrected visual acuity with fewer injections during the study period.

Investigators believe this connection could be used to prognosticate and prevent future cases of diabetic retinopathy.

The combination therapy of aflibercept and micropulsed yellow laser treatment results in good anatomical responses and substantially fewer intravitreal injections.

The mitochondria-targeting medication preserves photoreceptor health regardless of baseline photoreceptor outer segment thinning burden.

Compared to sham treatment, the PER-001 implant is safe, efficacious, and effective in reducing macular ischemia, vascular leakage, and microaneurysms.

Results from the DAVIO 2 trial have shown the equivalence of a single dose of EYP-1901 to aflibercept Q8W in visual acuity over 6 months.

Post hoc analyses of the TENAYA and LUCERNE phase 3 trials indicated important endpoints that could signal the potential for treatment interval extension.

Patient responses indicate that the device is simple and easy to use, and clinical data reflects its effectiveness in recognizing hallmark signals of AMD.

Results from an extension study of the PHOTON trial indicate longer-lasting visual and anatomic improvements in patients receiving aflibercept 8mg versus 2mg.

A recent analysis of data from the phase 3 YOSEMITE/RHINE trials has indicated a greater reduction in hard exudates using faricimab versus aflibercept.

In a trial studying faricimab’s efficacy in Black, Hispanic/Latino, and Native American patients with DME, investigators found results consistent with the YOSEMITE/RHINE trials.

The unsaturated fats from vegetable oils reduce inflammation and influence organ metabolism, resulting in lowered ALT, AST, and TBIL indexes.

A study investigating frequently used treatments, mean duration from first symptom to index date, and disease phenotypes found most cases are mild to moderate.

Combination therapy results in an overall reduction in 1-year mortality and hospitalizations compared to patients receiving SGLT2 inhibitors alone.

A recent study has suggested the efficacy of a common type 2 diabetes treatment in improving cardiac structure and metabolic control.

Although shown to have no connection to autism in multiple studies, the mercury-based agent will no longer be included in multidose influenza shots.

Announced by Aldeyra Therapeutics, Inc. on July 17, the FDA also assigned a PDUFA target action date of December 16, 2025.

Already approved by the FDA based on data from the first half of the PaTHway trial, 3-year extended results have indicated lasting efficacy.

The previously approved technology has already accomplished over 10,000 procedures for patients with various heart diseases, primarily including atrial fibrillation.

BaxHTN trial results showed baxdrostat led to a significant reduction of systolic blood pressure compared to placebo, with a favorable safety profile.

The FDA also announced an updated PDUFA date of December 13, 2025 for the self-administered nasal spray.